Coeptis Therapeutics, Inc.COEPNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +49.37% | -94.55% | -91.35% | -90.13% | -88.08% |
| Weighted Average Shares Diluted Growth | +49.37% | -94.55% | -91.35% | -90.13% | -88.08% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | -100.00% | -84.30% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +24.90% | +10.38% | +43.20% | +3.77% | +81.80% |
| Book Value per Share Growth | -26.47% | +1255.38% | +1618.94% | +769.27% | +2067.51% |
| Debt Growth | +31.43% | +14.28% | -15.96% | -25.33% | -84.23% |
| R&D Expense Growth | -84.00% | -66.07% | -88.85% | -27.21% | -27.66% |
| SG&A Expenses Growth | -58.11% | -25.87% | -80.18% | +89.81% | -81.38% |